Author: Charmaine Fraser

in Events, Other News

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending the BIO-Europe Spring digital conference on 28-30 March 2023. Physiomics Head of Business Development, Hayley Close, will be attending the conference digitally. Companies interested in meeting with Physiomics should email Hayley directly at hclose@physiomics.co.uk. Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980 Hybridan LLP (broker) Claire Louise...

10 Mar

Contract announcement

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics (“Bicycle”). The project relates to an undisclosed program and is expected to be completed in the Company’s current financial year. Physiomics CEO, Dr Jim Millen, commented: “We are...

07 Mar

Interim Results Statement for the six-month period ended 31 December 2022

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, today announces its unaudited financial results for the six months ended 31 December 2022. Please click here to read in full....

01 Mar

Mechanistic modelling: how much is enough?

in Blog

Cancer therapies are often associated with a ‘Goldilocks Window’ of optimal dosing: striking a balance where efficacy is maximised and toxicity is minimised. While mathematical modelling offers a powerful tool to inform optimal treatment approaches in cancer drug development, determining the right level of mechanistic detail to include in a model also requires careful consideration – hitting the right balance is both art and science. You...

13 Jan

Change in role of board director

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, announces that Dr Christophe Chassagnole's job title has changed from Chief Operating Officer to Chief Scientific Officer. This title aligns more closely with Dr Chassagnole's current role and responsibilities and the expectation that, going forward, he will spend more time focused on the Company's personalised...

11 Jan

Contract announcement

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has entered into a further contract with its existing client Cancer Research UK. Physiomics was first retained in July 2019 by Bicycle Therapeutics and Cancer Research UK to conduct Pharmacokinetics (PK), analyses (what the body does to the drug)...

09 Jan

Completion of PARTNER study

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the successful completion of its PARTNER study which was funded by a £150k “Connect” award from the National Institute for Health Research (“NIHR”) Invention for Innovation (“i4i”) programme (originally announced in March 2020). HIGHLIGHTS The NIHR funded PARTNER study builds...

23 Nov

Result of AGM

Physiomics plc (AIM: PYC), an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company’s offices in Oxford, were duly passed. Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980 Hybridan LLP (broker) Claire Louise Noyce +44 (0) 203 764...

10 Nov

Contract award